Parents in Wales are voicing concerns that their children may be left behind in early detection of Spinal Muscular Atrophy (SMA), a rare genetic condition, as screening protocols differ across the United Kingdom. While England and Scotland have begun introducing routine newborn screening for SMA via the heel-prick blood test, Wales has not yet implemented similar measures.
This disparity has led to fears among families that infants in Wales will face delayed diagnoses, potentially impacting treatment outcomes. Early detection and intervention are considered critical for SMA, as timely medication can help maintain muscle function and prevent further degeneration.
One family's experience highlights these concerns. Ophelia, born in September 2022, began showing physical delays around six months old, including reduced neck strength and deteriorating feeding. Despite parental observations, the initial message was that she would catch up. It wasn't until a meeting with her pediatrician that a referral to Noah's Ark Children's Hospital in Cardiff led to a request for an SMA blood test in February 2025. Ophelia was diagnosed nearly two-and-a-half years old.
"Data shows, if they are diagnosed at an earlier stage, medication outcomes are greater," said Ophelia's father, Warren, who works in children's social services. He noted that if his daughter had started her daily oral medication, which works to maintain muscle cells from degenerating, earlier, she might not have lost as much muscle function.
Following Ophelia's diagnosis, her family joined hundreds of others across the UK campaigning for SMA to be included in the standard newborn screening tests. The introduction of this screening in England and Scotland is seen as a significant step, but its absence in Wales creates a gap in early detection for Welsh babies.
The campaign for widespread SMA newborn screening gained significant public attention, bolstered by celebrity involvement. The differing approaches to implementing this screening across the UK's constituent countries raise questions about equitable healthcare access and the pace of adoption of new diagnostic technologies.